title: [Antibody response to a single injection of influenza vaccine among geriatric inpatients vaccinated annually].
abstract: To determine the efficacy of a single influenza vaccine administration in the elderly receiving annual influenza vaccination, antibody response to influenza vaccine was compared between once and twice injections in a geriatric cohort. Influenza vaccination had been done for 69 inpatients in the year prior to the study, and was administered twice for 34 of them and once for the other 35 during the study period. Influenza vaccine was injected twice to 77 inpatients who had not received influenza vaccine in the year prior to the study. Hemoagglutination inhibition (HI) antibody titer for influenza A/H1N1, A/H3N2, and B was measured before vaccination, after the first vaccination, after the second vaccination, and after the epidemic period, September 1995 to April 1996. HI antibody titer prior to vaccination was significantly higher in the patients who had received influenza vaccination the previous year. The influenza vaccine induced an increase in HI titer in almost all subjects, and the geometric mean of the HI titer after vaccination in the patients who received vaccine once was comparable to that of the patients injected vaccine twice. The number of patients with HI titers of over 128x increased, and the frequency ranged from 60.0% to 97.1% for the influenza viruses of the three subtypes. The frequency of HI titers over 128x was not significantly different among the three groups. The second vaccination did not increase the number of patients with HI titers over 128x when compared with the number after the first injection in the patients who had received influenza vaccine the previous year. These results suggest that prior vaccination does not diminish the antibody response to influenza vaccine in the elderly. The efficacy of a single influenza vaccination is comparable to that achieved by twice injections in the elderly receiving annual influenza vaccination.
authors.affiliation: Department of Clinical Research, Hara-Doi Hospital.
authors.forename: H
authors.initials: H
authors.lastname: Ikematsu
authors.forename: A
authors.initials: A
authors.lastname: Nabeshima
authors.forename: K
authors.initials: K
authors.lastname: Yamaji
authors.forename: K
authors.initials: K
authors.lastname: Kakuda
authors.forename: W
authors.initials: W
authors.lastname: Li
authors.forename: J
authors.initials: J
authors.lastname: Hayashi
authors.forename: S
authors.initials: S
authors.lastname: Goto
authors.forename: T
authors.initials: T
authors.lastname: Oka
authors.forename: T
authors.initials: T
authors.lastname: Shirai
authors.forename: S
authors.initials: S
authors.lastname: Yamaga
authors.forename: S
authors.initials: S
authors.lastname: Kashiwagi
mesh_terms: D000368:Aged / Q000502:physiology*; D000369:Aged, 80 and over / Q000502:physiology; D000917:Antibody Formation / Q000502:physiology*; D005260:Female; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007115:Immunization Schedule; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000276:immunology*; D008297:Male; D014611:Vaccination
chemical_list: D007252:Influenza Vaccines